Guided Therapeutics (GTHP) Cash from Operations (2016 - 2025)
Guided Therapeutics (GTHP) reported Cash from Operations of 291000.0 for Q4 2025, up 12.35% on a YoY basis from 259013.4 in Q4 2024, and down 5.05% sequentially from 277000.0 in Q3 2025.
Guided Therapeutics (GTHP) Cash from Operations (2016 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 10 years of Cash from Operations data on file, last reported at 291000.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Operations rose 12.35% year-over-year to 291000.0; the trailing twelve-month figure through Dec 2025 stood at 1068000.0 (up 4.56% YoY), and the FY2025 full-year result was 1068000.0, up 4.56% from the prior year.
- Cash from Operations fell to 291000.0 in Q4 2025, from 277000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 159000.0 in Q4 2021 to a low of 739000.0 in Q3 2021.
- A 5-year average of 350200.0 and a median of 334000.0 in 2023 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations surged 148.04% in 2021 and tumbled 313.21% in 2022, its largest moves.
- Tracing GTHP's Cash from Operations over 5 years: stood at 159000.0 in 2021, then tumbled by 313.21% to 339000.0 in 2022, then gained by 0.88% to 336000.0 in 2023, then advanced by 1.19% to 332000.0 in 2024, then climbed by 12.35% to 291000.0 in 2025.
- Business Quant data shows GTHP's Cash from Operations at 291000.0 in Q4 2025, 277000.0 in Q3 2025, and 169000.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.32 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 581.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 2.57 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 348.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 43.80 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 525.60 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 220.10 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 290.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 | -291,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -291,000.00 |
| Dec 31, 2025 | -291,000.00 |
| Sep 30, 2025 | -277,000.00 |
| Sep 30, 2025 | -277,000.00 |
| Jun 30, 2025 | -169,000.00 |
| Jun 30, 2025 | -169,000.00 |
| Mar 31, 2025 | -331,000.00 |
| Mar 31, 2025 | -331,000.00 |
| Dec 31, 2024 | -332,000.00 |
| Dec 31, 2024 | -332,000.00 |
| Sep 30, 2024 | -473,000.00 |
| Sep 30, 2024 | -473,000.00 |
| Jun 30, 2024 | -214,000.00 |
| Jun 30, 2024 | -214,000.00 |
| Mar 31, 2024 | -100,000.00 |
| Mar 31, 2024 | -100,000.00 |
| Dec 31, 2023 | -336,000.00 |
| Dec 31, 2023 | -336,000.00 |
| Sep 30, 2023 | -473,000.00 |
| Sep 30, 2023 | -473,000.00 |